Name
Renibus Therapeutics
What We Do
A clinical-stage biotech company dedicated to transforming outcomes in cardiothoracic surgery. Renibus’ first-in-class program, RBT-1 (stannic protoporfin/iron sucrose), is a potent inducer of anti-inflammatory and antioxidant pathways. Our pivotal Phase 3 registrational study is actively enrolling and aims to reduce postoperative complications and improve patient outcomes following cardiothoracic surgery.
Website
Categories
Cardiac, Critical Care, Pharmaceuticals
Address
181 Grand Ave
Suite 225
Southlake, TX 76092
United States
Suite 225
Southlake, TX 76092
United States